Congress subsidizes generic drug makers with no guarantee of lower prices

What it does

The PILLS Act creates two federal tax credits to incentivize domestic production of generic drugs and biosimilars: a 30–35% production credit on the value added by manufacturers, plus a 25% investment credit for building or upgrading facilities. Both credits phase out after 2030 and exclude companies deemed foreign entities of concern. The credits are transferable and available to eligible taxpayers, including non-profits and tax-exempt entities.

Why we flagged it

The bill's operative mechanism is a direct tax credit (foregone federal revenue) to incentivize domestic generic drug and biosimilar production. While framed as supply-chain security and affordability, it functions as a subsidy to pharmaceutical manufacturers with no binding price controls or public-benefit guarantees.

What the text implies

• Tax credits are transferable to non-manufacturing entities (nonprofits, tax-exempt organizations) under section 6417, potentially allowing financial intermediaries to capture and monetize the subsidy without producing drugs.
• No price-control or affordability requirement: manufacturers receiving credits face no obligation to lower generic drug prices or increase supply to underserved markets; the subsidy may simply improve profit margins.
• Phase-out after 2033 creates a cliff; manufacturers may front-load production before credits expire, then reduce domestic capacity, leaving supply vulnerable.
• Foreign entity of concern exclusion (referencing NDAA 2021 definitions) is opaque and may be subject to executive reinterpretation; unclear how it applies to multinational firms with US subsidiaries.
• Investment credit (section 48F) terminates for new construction after 2028, creating a rush to begin projects and potential waste if facilities are built speculatively.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill may lower generic drug prices and increase domestic manufacturing capacity by subsidizing production, benefiting patients and supply security. However, the credits are structured as tax expenditures (foregone federal revenue) with no price-control mechanism, meaning manufacturers may capture the subsidy without passing savings to consumers; the public bears the cost while private firms retain discretion over pricing.

Who stands to gain

• Generic drug manufacturers
• Biosimilar manufacturers
• Pharmaceutical contract manufacturers (CMOs)
• Tax credit investors and financial intermediaries (if credits are transferred)

Named in the bill

Internal Revenue Service (IRS), Food and Drug Administration (FDA), Generic drug manufacturers, Biosimilar manufacturers, Foreign entities of concern (NDAA 2021 definition), Tax-exempt entities and nonprofits (eligible for credit transfer)

Where it stands

2 cosponsors: 2 Republicans.

• Feb 14, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 14, 2025 — Referred to House Committee on Ways and Means · Congress.gov: “Referred to the House Committee on Ways and Means”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.